Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
July 08, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...
Yale Researchers to Present Data at AACR Conference Indicating That Novogen Compound NV-128 Uses mTOR Pathway to Induce Cell Death in Chemo-Resistant Ovarian Cancer Cells
March 25, 2008 08:01 ET
|
NOVOGEN LIMITED
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - March 25, 2008) - An abstract for an
oral presentation to be given at the Annual Meeting of the American
Association for Cancer Research, April 12...
Phenoxodiol Trials Highlighted at Ovarian Cancer Action International Conference
March 10, 2008 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - March 10, 2008) - The role of
the investigational drug phenoxodiol in restoration of chemosensitivity in
ovarian cancer patients...